Johnson & Johnson raises full-year guidance after strong Q2 sales growth

Johnson & Johnson increased its guidance for its full-year sales performance after notching 27% sales growth across all divisions year over year, according to its earnings report released Wednesday.

The New Brunswick, N.J.–based company reported $23.3 billion in sales during the second quarter due to market recovery and surging demand for medical devices, drugs and consumer-health products. Adjusted earnings were $2.48 per share, an increase of 48.5% year over year.

Its net income jumped 73%, to nearly $6.3 billion from $3.6 billion, in the second quarter of 2020, the company said.

Pharmaceuticals, including its one-shot Covid-19 vaccine, accounted for more than half its sales during the quarter,

→ Continue reading at Crain's New York Business

[ufc-fb-comments url=""]

Latest Articles

Related Articles